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Background. To understand regional burdens and inform delivery of health services, we conducted a systematic review and
meta-analysis to evaluate the effect of antiretroviral therapy (ART) on incidence of key opportunistic infections (OIs) in human
immunodeﬁciency virus (HIV)–infected adults in low- and middle-income countries (LMICs).
Methods. Eligible studies describing the cumulative incidence of OIs and proportion on ART from 1990 to November 2013 were
identiﬁed using multiple databases. Summary incident risks for the ART-naive period, and during and after the ﬁrst year of ART,
were calculated using random-effects meta-analyses. Summary estimates from ART subgroups were compared using meta-regression.
The number of OI cases and associated costs averted if ART was initiated at a CD4 count ≥200 cells/µL were estimated using Joint
United Nations Programme on HIV/AIDS (UNAIDS) country estimates and global average OI treatment cost per case.
Results. We identiﬁed 7965 citations, and included 126 studies describing 491 608 HIV-infected persons. In ART-naive patients,
summary risk was highest (>5%) for oral candidiasis, tuberculosis, herpes zoster, and bacterial pneumonia. The reduction in incidence
was greatest for all OIs during the ﬁrst 12 months of ART (range, 57%–91%) except for tuberculosis, and was largest for oral candidiasis,
Pneumocystis pneumonia, and toxoplasmosis. Earlier ART was estimated to have averted 857 828 cases in 2013 (95% conﬁdence in-
terval [CI], 828 032–874 853), with cost savings of $46.7 million (95% CI, $43.8–$49.4 million).
Conclusions. There was a major reduction in risk for most OIs with ART use in LMICs, with the greatest effect seen in the ﬁrst year
of treatment. ART has resulted in substantial cost savings from OIs averted.
Keywords. HIV-1; antiretroviral therapy; opportunistic infections; tuberculosis; low- and middle-income countries.
The impact of the introduction of highly active antiretroviral
therapy (ART) on the incidence and mortality of human immu-
nodeﬁciency virus (HIV)–associated opportunistic infections
(OIs) has been well documented in high-income countries
(HICs). This improved survival has been associated with a pro-
gressive shift in the pattern of comorbidities, with an increasing
contribution of chronic liver disease due to hepatitis C and B,
cardiovascular disease, and non-AIDS malignancies [1–4].
In low- and middle-income countries (LMICs), the global
rollout of ART has led to >15 million patients on ART, and a
decline in HIV-related deaths by 40% since 2004 [5, 6]. OIs re-
main the major driver of HIV-associated morbidity and
mortality, accounting for the substantially higher mortality ob-
served in LMICs [7], but the ART impact on speciﬁc OIs has
not been well documented, mainly because there is no routine
country-level monitoring for OIs.
Reliable data on the relative burden of different OIs before
and after ART initiation in different geographic regions is crit-
ical for planning of health services, including procurement of
relevant drugs and diagnostics. The few previous reviews on
OI incidence either preceded the global scale-up of ART or ad-
dressed only speciﬁc OIs or regions [8, 9]. We have undertaken a
comprehensive systematic review and meta-analysis to estimate
the incidence of key OIs in HIV-infected adults before and after
the introduction of ART in LMICs across 3 regions (sub-Saharan
Africa, Asia, and Latin America and the Caribbean), and to eval-
uate the magnitude of effect of ART on the incidence of these
OIs during and after the ﬁrst year of treatment.
METHODS
Search Strategy and Selection Criteria
A systematic review of the literature was performed using Med-
line, Embase, Cumulative Index to Nursing and Allied Health
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Literature, Latin American and Caribbean Health Sciences Lit-
erature, Global Health, CAB Abstracts, Web of Science, and the
Cochrane Library of Systematic Reviews from January 1990 to
21 November 2013, and conference proceedings (Conferences
on Retroviruses and Opportunistic Infections, Google, and
Web of Science) from 1997 to 2010, published in English, Span-
ish, French, and Portuguese. The gray literature was searched
using Google Scholar and key sources such as the World Health
Organization (WHO) website. Eligible studies documented the
incidence of 16 OIs and coinfections among HIV type 1–infect-
ed adults (aged ≥18 years) in LMICs, as deﬁned by the 2009
World Bank classiﬁcation [10]. Our search was conducted ac-
cording to Meta-analysis of Observational Studies in Epidemi-
ology and Preferred Reporting Items for Systematic Reviews
and Meta-analyses guidelines and is reported in Supplementary
Appendix 1 [11, 12]. Key OIs included cryptococcal meningitis,
Pneumocystis pneumonia (PCP), oral and esophageal candidia-
sis, cerebral toxoplasmosis, cryptosporidial diarrhea, genital
ulcer disease (GUD) attributed to herpes simplex virus, herpes
zoster, Kaposi sarcoma, cytomegalovirus retinitis, bacterial in-
fections (pneumonia, enteritis, and bacteremia), and Mycobac-
terium tuberculosis (hereafter “tuberculosis”). Tuberculosis was
classiﬁed as unspeciﬁed forms where data was only provided
on the incidence of “tuberculosis,” and pulmonary tuberculosis
(PTB) and extrapulmonary tuberculosis (EPTB), where these
forms were speciﬁed. Criteria for OI diagnoses are described in
Supplementary Appendix 2.
Eligible studies of incidence included prospective and retro-
spective observational cohort studies, and randomized con-
trolled trials (RCTs). Where the RCT involved evaluation of a
treatment for the OI under study, only data from the placebo
arm were used.
All titles and abstracts were screened by independent reviewers
(A. L. and G. G.) to identify potentially relevant articles. The full
articles were eligible if they provided data from which a cumula-
tive incident risk for individual OIs could be calculated. We ex-
cluded studies that included pregnant women or children, where
the majority of patients had HIV type 2, were based on preselect-
ed populations such as those with a diagnosis of meningitis or
pneumonia, or those with no reliable denominator. Studies
where only repeated measures were reported and the incident
risk of the ﬁrst event could not be calculated were excluded.
Where there were multiple reports from 1 cohort, we selected
the most recent report with the longest follow-up. Data extracted
for each study included study design, duration of follow-up, ART
status, use of cotrimoxazole (CTX) prophylaxis, baseline CD4
counts, and diagnostic methods (Supplementary Appendix 2).
Study Deﬁnitions
ART status was categorized as either “ART naive” (including stud-
ies with <10% of patients on ART, or when conducted prior to the
availability of ART), or “ART exposed” (including studies with
≥80% of patients on ART). We excluded studies where the pro-
portion on ART was ≥10% and <80%, or where data on ART use
were not provided. To determine the relative impact of ART at
lower CD4 counts when there is an increased risk of IRIS, the
ART-exposed category was further stratiﬁed according to duration
of time on ART: during the ﬁrst year on ART, after the ﬁrst year of
ART, and during an unspeciﬁed time on ART where it spanned
both periods or was not stated. Multiple estimates were extracted
from articles if results were stratiﬁed according to ART status.
Where incidence was provided according to different CD4
count strata, an overall estimate of incidence was presented based
on the mean or median CD4 count of the population.
Statistical Analyses
Since few studies reported incidence rates using person-years
at risk, we calculated a cumulative incident risk of developing
a speciﬁc OI (termed “risk” hereafter) for each study, deﬁned as
the cumulative number of new cases during follow-up divided by
the number of persons at risk, and presented this as a percentage.
Ninety-ﬁve percent conﬁdence intervals (95% CIs) were extracted
from the article, or calculated from raw data if not reported.
To estimate summary risks for each OI across studies,
the variances of raw percentages were stabilized using Tukey–
Freeman arcsine square root transformation [13]. Summary
risks were generated using random-effects meta-analysis to
adjust for high between-study variability. Between-study het-
erogeneity was evaluated using I2 and the P value for heteroge-
neity (Cochran Q statistic) [14]. Meta-analyses were performed
using R software version 2.13.1. For OIs with data from ≥15
studies, we performed meta-regression analyses to calculate an
adjusted odds ratio (aOR) and estimate the effect of each ART
category on risk. The summary risks were transformed using
empirical logistic transformation and univariable meta-regression
was performed. ART categories with <3 studies were not included
in the meta-regression.
In addition, we used meta-regression to explore potential
sources of heterogeneity, including region, duration of time on
ART, use of CTX prophylaxis, baseline CD4 count, method of
OI diagnosis, and duration of follow-up. Univariable and multi-
variable meta-regression analyses were performed: time on ART,
median follow-up time, and region were included a priori in mul-
tivariable models, and any variables from the univariable analysis
with a P value P≤ .20. Those variables that remained signiﬁcant
with a P≤ .05 were retained in the ﬁnal model. Meta-regression
was performed using Stata software version 13. Meta-regression
was also used to compare regional incidence of OIs across ART
categories, for OIs for which there was at least 1 study per region,
in the same manner as for the ART analysis.
OI Cases Averted by the Use of ART
The estimated number of HIV-infected adults with CD4
counts <200 cells/µL for 156 LMICs were obtained from
2013 Joint United Nations Programme on HIV/AIDS
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(UNAIDS) country estimates [15–17]. The number of OI cases
averted through use of ART for the year 2013 was calculated by
applying the difference in estimates of OI risk in ART-naive
participants and in those during their ﬁrst year of ART to
the estimated population with a CD4 count ≤200 cells/µL,
for each region. The annual savings per OI averted were calcu-
lated for OIs where there was some evidence from the meta-
analysis of an effect of ART (P < .20), and where there was
data available for an average treatment cost per case [18], by
multiplying the number of OI cases averted by the treatment
cost per case. Uncertainty ranges were estimated from 1000
Monte Carlo draws of the difference in estimates of risk, as-
suming a normal distribution.
RESULTS
The search strategy identiﬁed 6816 journal citations and 1025
conference abstracts; 952 full text reports were screened and
126 studies met the inclusion criteria (122 full-text articles and
4 conference abstracts; Figure 1). There were 67 studies describing
the incidence of 12 OIs, and 94 studies for the different types
of tuberculosis; 28 studies describing cytomegalovirus were ex-
cluded due to widely varying case deﬁnitions. Table 1 summarizes
Figure 1. Flowchart of study selection. Abbreviations: ART, antiretroviral therapy; CMV, cytomegalovirus; HIC, high-income country; OI, opportunistic infection; TB,
tuberculosis.
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Table 1. Characteristics of Included Studies Describing Opportunistic Infections, by Region
Characteristic Study Design No. of Study Patients (Range)
Baseline CD4 Count,
Range, Cells/µL
Laboratory/Radiological
Confirmationa, no./No. (%)
Cryptococcal meningitis
Sub-Saharan Africa 4 RCT, 12 cohorts 186 899 (60–175 212) 16–461 9/16 (56)
Asia 1 RCT, 8 cohorts 16 655 (54–10 904) 8–227 5/9 (56)
LAC 3 cohorts 1740 (318–1057) 64–208 2/3 (66)
Pneumocystis pneumonia
Sub-Saharan Africa 1 RCT, 7 cohorts 183 619 (270–175 212) 128–499 5/8 (63)
Asia 9 cohorts 10 902 (54–5040) 26–130 7/9 (78)
LAC 6 cohorts 2420 (123–1057) <200–492 3/6 (50)
Oral candidiasis
Sub-Saharan Africa 2 RCT, 8 cohorts 20 531 (110–8409) 200–527 1/10 (10)
Asia 1 RCT, 6 cohorts 4152 (66–1982) 73–227 1/7 (14)
LAC 2 cohorts 1217 (160–1057) <200–477 0/2
Esophageal candidiasis
Sub-Saharan Africa 3 RCT, 5 cohorts 8627 (248–2446) <100–322 1/8 (13)
Asia 1 RCT, 3 cohorts 2005 (54–1246) 43–73 0/4
LAC 2 cohorts 478 (160–318) 477 0/2
Herpes zoster
Sub-Saharan Africa 1 RCT, 7 cohorts 4305 (101–1620) 135–461 0/8
Asia 4 cohorts 2457 (108–1253) 115–227 0/4
LAC 2 cohorts 1217 (160–1957) <200–477 0/2
Genital herpes simplex or ulcer disease
Sub-Saharan Africa 4 RCT, 7 cohorts 4916 (60–1215) 128–500 2/11 (18)
Asia 5 cohorts 5098 (54–1503) 43–129 0/5
LAC 1 cohort 318 208 0/1
Kaposi sarcoma
Sub-Saharan Africa 2 RCT, 15 cohorts 275 298 (60–175 212) 118–461 3/17 (18)
Asia 1 cohort 76 NA 0/1
LAC 4 cohorts 2137 (145–1057) 183–492 0/4
Cerebral toxoplasmosis
Sub-Saharan Africa 1 RCT, 9 cohorts 6914 (124–1620) 128–461 5/10 (50)
Asia 5 cohorts 3087 (54–1246) 43 2/5 (40)
LAC 4 cohorts 1680 (145–1057) <200–492 1/4 (25)
Cryptosporidium diarrhea
Sub-Saharan Africa 1 RCT, 5 cohorts 4413 (248–1215) 128–252 5/6 (83)
Asia 4 cohorts 1484 (54–1276) 43 3/4 (75)
LAC 1 cohort 160 477 1/1 (100)
Mycobacterium tuberculosis (unspecified)
Sub-Saharan Africa 10 RCT, 42 cohorts 131 490 (60–14 422) 65–499 44/52 (85)
Asia 15 cohorts 24 496 (54–5099) 23–783 10/15 (67)
LAC 1 RCT, 9 cohorts 15 425 (60–8128) 105–492 7/10 (70)
Pulmonary tuberculosis
Sub-Saharan Africa 1 RCT, 23 cohorts 62 884 (53–5980) 50–461 19/24 (79)
Asia 1 RCT, 8 cohorts 6972 (76–2984) 26–350 7/9 (78)
Extrapulmonary tuberculosis
Sub-Saharan Africa 1 RCT, 19 cohorts 58 926 (86–5980) 50–461 17/20 (85)
Asia 8 cohorts 6772 (76–2984) 26–350 6/8 (75)
LAC 1 cohort 617 NA 1/1 (100)
Bacterial pneumonia
Sub-Saharan Africa 4 RCT, 9 cohorts 6277 (53–1792) 200–461 13/13 (100)
Asia 1 cohort 134 NA 1/1 (100)
Isolated bacteremia
Sub-Saharan Africa 2 RCT, 6 cohorts 2312 (101–792) 135–461 8/8 (100)
Asia 1 cohort 108 <200 1/1 (100)
Bacterial enteritis
Sub-Saharan Africa 2 RCT, 7 cohorts 5603 (101–1792) 135–461 9/9 (100)
Clinical response to empiric treatment without imaging or laboratory confirmation or unspecified means of diagnosis is considered non–laboratory confirmed.
Abbreviations: LAC, Latin America and the Caribbean; NA, data not available; RCT, randomized controlled trial.
a Laboratory confirmation for cryptococcal meningitis: cerebrospinal fluid cryptococcal antigen or India ink; for Pneumocystis pneumonia: chest radiograph and sputum cytology or clinical
response; for oral candidiasis: fungal culture; for esophageal candidiasis: endoscopy and fungal culture; for herpes zoster or genital herpes simplex: Tzanck smear or polymerase chain
reaction assay; for Kaposi sarcoma: biopsy and histology; for cerebral toxoplasmosis: computed tomographic brain scan, serology, and response to treatment; for Cryptosporidium diarrhea:
modified Ziehl–Neelsen stool stain; for all forms of tuberculosis: acid-fast bacilli stain and/or mycobacterial culture; for all bacterial diseases: blood, sputum or stool cultures; for bacterial
pneumonia: chest radiograph.
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characteristics of included studies, which described data from
89 cohorts or trials in 38 countries; 85 (67%) studies were
from sub-Saharan Africa (Figure 2). A total of 491 608 partici-
pants were included in our analysis: 432 469 patients in sub-Sa-
haran Africa, 42 243 in Asia, and 16 896 in Latin America
(Table 1). Study size ranged from 54 to 175 212 participants
(median, 765 [interquartile range {IQR}, 248–1646]). Length
of follow-up was available for 67 studies (53%), and ranged
from 3 to 78 months (median, 24 months [IQR, 12–35
months]). A CD4 count <200 cells/µL, or the presence of a
WHO stage III or IV disease, were the criteria for ART initia-
tion in most studies. Laboratory or radiological conﬁrmation
was available in >75% of studies for diagnosis of Cryptosporid-
ium diarrhea, tuberculosis, and bacterial infections, and in
<50% of studies for candidiasis, herpes zoster, GUD, Kaposi
sarcoma, and cerebral toxoplasmosis.
Incidence of OIs in ART-Naive Participants
The most common OIs in ART-naive participants were oral can-
didiasis (19.1% [95% CI, 13.0%–27.3%]), unspeciﬁed tuberculo-
sis (10.0% [95% CI, 8.7%–11.5%]), herpes zoster (9.4% [95% CI,
6.7%–13.2%]), PTB (9.0% [95% CI, 6.8%–11.8%]), bacterial
pneumonia (6.1% [95% CI, 4.3%–8.4%]), and GUD (6.0%
[95% CI, 2.7%–12.8%]) (Table 2 and Figure 3A). There were
some differences in incidence across the regions based on a com-
parison of the 11 OIs and coinfections for which there was at least
1 study per region (see Supplementary Appendix 3 and Supple-
mentary Figure 1A–O for region-speciﬁc incidence and 95% CI).
There were no data available in ART-naive participants in Latin
America for esophageal candidiasis, GUD, Cryptosporidium,
PTB, or bacterial infections, or in Asia for bacteremia or enteritis.
Overall, there was a slightly lower reported risk of all OIs except
GUD and bacterial pneumonia in sub-Saharan Africa; unspeci-
ﬁed tuberculosis was most commonly diagnosed in Asia (15.2%
[95% CI, 7.8%–27.6%]), and PCP (8.4% [95% CI, .5%–24.5%]),
toxoplasmosis (3.3% [95% CI, 2.4%–4.4%]), and Kaposi sarcoma
(2.4% [95% CI, .7%–8.0%]) in Latin America.
Effect of ART on Incidence of OIs
During the ﬁrst year of ART, the risk of all OIs declined to <2%,
except for unspeciﬁed tuberculosis (4.2% [95% CI, 3.5%–
4.9%]), PTB (3.5% [95% CI, 2.9%–4.3%]), herpes zoster (2.3%
[95% CI, 1.6%–3.3%]), and oral candidiasis (2.3% [95% CI,
1.6%–3.4%]), which remained the most common OIs (Table 2
and Figure 3B).
Meta-regression analysis found that the greatest effect of ART
was seen during the ﬁrst year of treatment, and ranged from a
57%–91% reduction. There were few studies providing informa-
tion on risk after the ﬁrst year of ART except for unspeciﬁed
tuberculosis and PTB. The magnitude of effect of ART during
the ﬁrst year was greatest for oral candidiasis (aOR, 0.09 [95%
CI, .03–.25]), cerebral toxoplasmosis (aOR, 0.12 [95% CI,
.03–.57]), and PCP (aOR, 0.13 [95% CI, .03–.62]) (Table 2).
There was also a non–statistically signiﬁcant reduction for cryp-
tococcal meningitis (aOR, 0.37 [95% CI, .12–1.18]), herpes zos-
ter (aOR, 0.39 [95% CI, .15–1.03]), Kaposi sarcoma (aOR, 0.13
[95% CI, .01–1.70]), esophageal candidiasis (aOR, 0.31 [95% CI,
.06–1.64]), and GUD (aOR, 0.18 [95% CI, 0–12.03]). There was
a 57%–64% reduction in risk of tuberculosis (unspeciﬁed: aOR,
0.36 [95% CI, .24–.55]; PTB: aOR, 0.38 [95% CI, .22–.67]; and
EPTB: aOR, 0.43 [95% CI, .25–.77]). After the ﬁrst year, there
was a further reduction in risk for PTB (aOR, 0.13 [95% CI,
.04–.43]) and unspeciﬁed tuberculosis (aOR, 0.26 [95% CI,
.15–.45]). Summary risks for unspeciﬁed time on ART also
Figure 2. Low- and middle-income countries reporting the incidence of key opportunistic infections and antiretroviral therapy status. Thirty-eight countries provided included
data. Green represents Latin America and the Caribbean, blue represents sub-Saharan Africa, and purple represents Asia. Color darkness reflects the number of included
studies, with darker shading representing more studies. High-income countries were not eligible for inclusion.
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showed a reduction in incidence for each OI, although this was
less marked than during the ﬁrst year of ART.
In the meta-regression analysis of the effect of region on in-
cidence (Supplementary Appendix 3 and Supplementary
Table 1), compared with sub-Saharan Africa, there was an
increased risk of PCP in studies from Latin America (aOR,
10.58 [95% CI, 2.52–44.31]) and Asia (aOR, 9.88 [95% CI,
2.68–36.39]); and in Asia for toxoplasmosis (aOR, 7.46 [95%
CI, 2.31–24.14]), cryptococcal meningitis (aOR, 2.71 [95% CI,
1.33–5.50]), and EPTB (aOR, 2.35 [95% CI, 1.31–4.23]). There
Table 2. Estimated Summary Incident Risks for Opportunistic Infections, by Antiretroviral Status and Duration of Antiretroviral Therapy Use
Opportunistic
Infection
Summary of Incident Risk, % (95% CI) (No. of Studies) Adjusted Odds Ratioa,b (95% CI)
P
ValuebART-Naive <1 y ART ≥1 y ART
Unspecified Time
on ART <1 y ART ≥1 y ART
Unspecified
Time on ART
Cryptococcal
meningitis
1.7 (1.0–2.9) (16) 0.7 (.3–1.9) (4) 6.9 (4.4–10.3) (1) 0.8 (.5–1.3) (13) 0.37 (.12–1.18) . . . 0.47 (.22–.99) .02
Pneumocystis
pneumonia
2.8 (1.1–6.9) (10) 1.0 (.7–1.3) (4) 5.5 (1.4–20.1) (2) 0.7 (.1–4.0) (9) 0.13 (.03–.62) . . . 0.33 (.10–1.13) .02
Oral candidiasis 19.1 (13.0–27.3) (10) 2.3 (1.6–3.3) (4) 1.2 (.9–1.5) (1) 5.0 (3.2–7.7) (7) 0.09 (.03–.25) . . . 0.20 (.08–.51) <.001
Esophageal
candidiasis
3.0 (1.7–5.3) (8) 0.2 (.1–.7) (1) 13.2 (9.7–17.4) (1) 1.0 (.5–2.0) (6) 0.31 (.06–1.64) . . . . . . .15
Herpes zoster 9.4 (6.7–13.2) (7) 2.3 (1.6–3.3) (2) . . . 4.3 (2.3–8.0) (7) 0.39 (.15–1.03) . . . . . . .06
Herpes simplex/GUD 6.0 (2.7–12.8) (10) 1.2 (.2–7.7) (3) 5.7 (3.4–8.8) (1) 4.6 (1.8–11.3) (5) 0.18 (0–12.03) . . . 0.58 (.04–7.50) .63
Kaposi sarcoma 1.2 (.6–2.3) (14) 0.2 (0–1.5) (3) 2.0 (.4–8.5) (2) 0.5 (.3–.8) (6) 0.13 (.01–1.70) . . . 0.77 (.11–5.20) .26
Cerebral
toxoplasmosis
1.1 (.6–2.1) (11) 0.6 (.2–1.7) (4) 11.0 (7.8–15.0) (1) 0.5 (.2–1.1) (6) 0.12 (.03–.57) . . . 0.55 (.21–1.49) .03
Cryptosporidium
diarrhea
2.0 (.9–4.6) (6) 0.3 (0–2.9) (2) . . . 0.5 (.2–1.3) (3) . . . . . . . . . NA
Mycobacterium
tuberculosis
(unspecified)
10.0 (8.7–11.5) (45) 4.2 (3.5–4.9) (33) 2.8 (1.2–6.5) (14) 6.8 (4.4–10.3) (22) 0.36 (.24–.55) 0.26 (.15–.45) 0.66 (.42–1.04) <.001
Pulmonary
tuberculosis
9.0 (6.8–11.8) (21) 3.5 (2.9–4.3) (15) 1.0 (.2–5.8) (3) 4.9 (3.1–7.7) (15) 0.38 (.22–.67) 0.13 (.04–.43) 0.52 (.52–.91) <.001
Extrapulmonary
tuberculosis
2.9 (2.0–4.1) (19) 1.2 (.9–1.7) (14) 0.2 (.1–.4) (1) 2.2 (1.4–3.3) (14) 0.43 (.25–.77) . . . 0.61 (.33–1.11) .02
Bacterial pneumonia 6.1 (4.3–8.4) (9) 0 (0–3.3) (1) . . . 3.4 (1.0–11.1) (3) . . . . . . . . . NA
Bacteremia 5.3 (3.9–7.3) (5) 0.7 (.2–3.5) (2) . . . 2.9 (.2–37.3) (2) . . . . . . . . . NA
Bacterial enteritis 5.3 (2.6–8.8) (6) . . . . . . 1.2 (.1–9.8) (3) . . . . . . . . . NA
Individual reports can be included in >1 ART category.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; GUD, genital ulcer disease; NA, numbers insufficient to perform analysis.
a Reference is naive population, adjusted for region, ART status, and median follow-up time.
b Determined by random-effects logistic meta-regression; ART categories with ≤3 studies were not included in the meta-regression analysis.
Figure 3. Summary incident risk of each opportunistic infection by region and overall for antiretroviral therapy (ART)–naive patients (A), and during the first year of ART (B).
Abbreviations: GUD, genital ulcer disease; HSV, herpes simplex virus; PCP, Pneumocystis pneumonia; TB, tuberculosis.
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were no signiﬁcant regional differences for oral or esophageal
candidiasis, herpes zoster, or GUD.
There was between-study heterogeneity in incidence of OIs
across studies and regions, and the most important sources of
heterogeneity were baseline CD4 count for cryptococcal menin-
gitis (I2 = 56.4% for CD4 counts 200–499 cells/µL) and oral can-
didiasis (I2 = 54.9% for unspeciﬁed CD4 count), but no factor
was identiﬁed that predominately explained the source of this
heterogeneity. The use of CTX prophylaxis did not explain the
heterogeneity in incidence of PCP or toxoplasmosis, where esti-
mates of I2 were high for all categories of CTX exposure.
Global Impact of ART Use on OIs Averted and Cost Savings
The use of ART before a decline in CD4 count to <200 cells/
µL was estimated to have averted 857 828 OI cases (95%
CI, 828 032–874 853) in 2013 (Table 3): 599 711 (95% CI,
595 974–629 673) in sub-Saharan Africa, 195 312 (95% CI,
194 096–205 071) in Asia, and 38 198 (95% CI, 37 962–
40 109) in Latin America. The most common OIs, oral candi-
diasis (366 661 [95% CI, 356 835–368 546]) and tuberculosis
(182 017 [95% CI, 173 392–190 468]), accounted for the great-
est number of OIs averted. Estimated cost savings in OI treat-
ment during 2013 were $46.7 million (95% CI, $43.8–$49.4
million) for 6 OIs with global estimates of treatment costs
per case. Most savings from ART use were due to averted
cases of tuberculosis, with an estimated $33.3 million (95%
CI, $31.6–$34.8 million) in savings.
DISCUSSION
This systematic review and meta-analysis is the most compre-
hensive assessment of the global and regional incidence and
effect of ART for 15 OIs, based on an analysis of almost
500 000 HIV-infected adults. Overall, there was a substantial
reduction in risk during the ﬁrst year of ART, ranging from
57% to 91%, which was greatest for oral candidiasis, toxoplas-
mosis, and PCP. The magnitude of effect of ART is more pro-
nounced than that observed in HICs, which is consistent with
evidence that levels of treatment adherence and immune re-
covery in LMICs are comparable to those in HICs [19–28].
A similar reduction in incidence of OIs has been observed in
a companion meta-analysis of children in LMICs [29], al-
though the incidence of bacterial pneumonia was substantially
higher in children, whereas herpes zoster was more frequent in
ART-naive adults.
We had insufﬁcient studies for a robust analysis of the effect
of ART on bacterial infections, but showed some effect of ART
on bacterial pneumonia. Data from other studies show that the
level of immune suppression has little effect on the acquisition
of bacterial infections [30, 31]. Overall, it is likely that some of
the reduction in risk with ART was due to increasing CTX che-
moprophylaxis [26]. This highlights the importance of provid-
ing CTX to all HIV-infected adults and children in LMICs. Ta
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There were few studies providing data on longer-term effects
of ART, other than for unspeciﬁed tuberculosis and PTB. The ef-
fect of ART was greater after 1 year, and is consistent with other
studies showing a progressive time-dependent reduction in risk
over the ﬁrst 2–3 years of ART [32, 33]. This can be explained
by the occurrence of tuberculosis across a wide range of CD4
counts, with less of a protective effect of early immune restora-
tion, and because of the signiﬁcant rate of unmasking immune
reconstitution inﬂammatory syndrome (IRIS) in the ﬁrst months
after ART initiation. It is likely that further stratiﬁcation within
the ﬁrst year of therapy would have revealed variations in the ef-
fect of ART for all OIs, with an increase in diagnoses seen in the
ﬁrst 3 months and then a gradual decline in incidence. This could
explain why duration of follow-up did not seem to impact study
heterogeneity, as most cases occur early during ART.
We were limited in our ability to draw deﬁnitive conclusions
on the importance of regional differences, due to some impreci-
sion in the estimates, as well as variability in diagnostic methods
and inconsistency in ascertainment of cases. The low incidence of
PCP and other OIs in sub-Saharan Africa may be attributable to
limited diagnostic resources and capacity, rather than true lower
endemicity [34], and is supported by the lack of regional varia-
tion in those OIs that are predominantly diagnosed clinically.
Our analyses also provide a valuable approximation of num-
ber of OIs averted, and potential cost savings of $47 million per
annum, from initiating ART before the CD4 count declines to
<200 cells/µL. These estimates likely underestimate the full sav-
ings as they do not capture variation in treatment costs across
different countries or include the diagnostic costs. Although the
costs of ART tend to be higher than the costs of treating OIs, the
savings from averting these OIs are a substantial additional ben-
eﬁt of ART.
As with other meta-analyses of observational studies, there
was high heterogeneity due to inclusion of diverse populations
with varying times of follow-up, variability in reporting of CTX,
ART regimen, and duration of ART, and lack of data on impor-
tant confounders such as baseline CD4 count. Few studies dis-
tinguished between presumptive and conclusive OI diagnoses.
There were also signiﬁcant gaps in data from regions such
as Latin America, a predominance of data from sub-Saharan
Africa, and large cohorts in Uganda, Cote D’Ivoire, and South
Africa, and from older cohorts with more advanced immunode-
ﬁciency at ART initiation, which precluded an evaluation of the
impact of initiating ART at higher CD4 counts.
In conclusion, the profound effect of ART on the incidence of
most HIV-related OIs is the key reason for the observed global
decline in HIV-related mortality, and highlights the continued
priority of expanding ART access. It is estimated that expanding
ART access to all people living with HIV will avert 21 million
AIDS-related deaths by 2030. The WHO now recommends
ART for all HIV-infected persons [35], based on the Strategic
Timing of Antiretroviral Treatment and Trial of Early
Antiretrovirals and Isoniazid Preventive Therapy in Africa trials
ﬁndings of a major reduction in AIDS and non-AIDS-related
morbidity and mortality with ART initiation at a CD4 count
>500 cells/µL [36, 37], as well as evidence of a marked impact
on HIV transmission [32]. A signiﬁcant proportion of HIV-in-
fected persons continue to present with advanced disease, and
so other measures to reduce mortality remain important. This in-
cludes prompt initiation of CTX prophylaxis, screening for tu-
berculosis and cryptococcal disease, and use of isoniazid and
ﬂuconazole chemoprophylaxis in those with advanced disease.
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